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Introduction
Macrophage activation syndrome (MAS) is a life-
threatening complication of childhood systemic inflam-
matory disorders. HMGB1 is a nuclear protein that
extracellularly orchestrates key events in inflammation.
Recent data revealed that different redox states of three
cysteines within HMGB1 render it with mutually exclu-
sive activities: reduced all-thiol-HMGB1 exerts chemo-
tactic activity, disulfide-HMGB1 cytokine-inducing
effects, and terminally oxidized sulfonyl-HMGB1 with-
out inflammatory activity.
Objectives
This study was set to assess the kinetics of HMGB1 in
four patients with severe MAS, on the basis of SoJIA
(n=3) or SLE (n=1), and to identify which HMGB1
redox isoforms appear during different disease stages.
Methods
Serial serum samples were analyzed with ELISA for
detection of HMGB1, IL-1b, IL-1a, IL-18, IFN-g and
MCP-1. Isoforms of HMGB1 were identified and quanti-
fied by high-resolution and sensitive proteomic mass
spectrometry (MS).
Results
At onset of MAS three patients had ongoing biologic
therapy: two with tocilizumab; one with combination
anakinra and CsA. All patients were intensive care trea-
ted, three with severe CNS involvement, and all were
steroid-resistant. Mass spectrometric characterization
revealed early increased levels of predominantly cyto-
kine-inducing disulfide-HMGB1 during severe disease
activity. Inflammatory control was achieved in all patients
with etoposide, given 50-100mg/m2/week. After initiation
of treatment and resolving inflammation the HMGB1
levels declined and changed to the non-inflammatory iso-
form. IFN-g and ferritin appeared concomitant with
HMGB1, whereas IL-18 and MCP-1 levels peaked later.
As opposed to other studies in MAS, IL-1 could not be
detected in any of the patients.
Conclusion
This work provides new insights in HMGB1 biology
suggesting different roles of HMGB1 during the course
of the highly inflammatory condition MAS, indicating
that the observed elevated HMGB1 levels are not just a
product of the inflammation but rather contribute to
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